Medical references​

1. Hanifin JM, Reed ML, Eczema Prevalence and Impact Working Group. A population-based survey of eczema prevalence in the United States. Dermat Contact Atopic Occup Drug. 2007;18(2):82-91.

2. Margolis JS, Abuabara K, Bilker W, Hoffstad O, Margolis DJ. Persistence of mild to moderate Atopic Dermatitis. JAMA Dermatol. 2014;150(6):593-600. doi:10.1001/jamadermatol.2013.10271. 

3. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132-1138. doi:10.1016/j.jaci.2013.08.031. 

4. Saavedra JM, Boguniewicz M, Chamlin S, et al. Patterns of Clinical Management of Atopic Dermatitis in Infants and Toddlers: A Survey of Three Physician Specialties in the United States. JPediatr.2013;163(6):1747-1753.doi:10.1016/j.jpeds.2013.06.073. 

5. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis — Section 2. J Am Acad Dermatol.2014;71(1):116-132. doi:10.1016/j.jaad.2014.03.023. 

6. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis — Section 1. J Am Acad Dermatol.2014;70(2):338-351. doi:10.1016/j.jaad.2013.10.010. 

7. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis — Section 3. J Am Acad Dermatol. 2014;71(2):327-349.doi:10.1016/j.jaad.2014.03.030.

8. Sidbury R, Tom WL, Bergman JN, et al. Guidelines of Care for the Management of Atopic Dermatitis Part 4: Prevention of Disease Flares and Use of Adjunctive Therapies and Approaches. J Am Acad Dermatol.2014;71(6):1218-1233. doi:10.1016/j.jaad.2014.08.038. 

9. Stern RS, Nelson C. The diminishing role of the dermatologist in the office-based care of cutaneous diseases. J Am Acad Dermatol.1993;29(5 Pt 1):773-777. 

10. Hanifin JM. Diagnostic features of atopic dermatitis. Acta Derm Venereol.1980;92:44-47

11. Su J, Kemp A, Varigos G, Nolan T. Atopic eczema: its impact on the family and financial cost. Arch Dis Child. 1997;76(2):159-162. 

12. Elias PM, Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Curr Opin Allergy Clin Immunol. 2009;9(5):437-446. doi:10.1097/ACI.0b013e32832e7d36.

13. Lindh JD, Bradley M. Clinical Effectiveness of Moisturizers in Atopic Dermatitis and Related Disorders: A Systematic Review. Am J Clin Dermatol.2015;16(5):341-359. doi:10.1007/s40257-015-0146-4. 

14. Lynde CW. Moisturizers: what they are and how they work. Skin Ther Lett.2001;6(13):3-5. 

15. Chiang C, Eichenfield LF. Quantitative assessment of combination bathing and/or moisturizing regimens on skin hydration in atopic dermatitis.Pediatr Dermatol. 2009;26(3):273-278. doi:10.1111/j.1525-1470.2009.00911.x

16. Simpson E, Trookman NS, Rizer RL, et al. Safety and tolerability of a body wash and moisturizer when applied to infants and toddlers with a history of atopic dermatitis: results from an open-label study. Pediatr Dermatol. 2012;29(5):590-597. doi:10.1111/j.1525-1470.2012.01809.x

17. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess Winch Engl. 2000;4(37):1-191. 

18. Long CC, Mills CM, Finlay AY. A practical guide to topical therapy in children. Br J Dermatol. 1998;138(2):293-296. 

19. Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2011;164(2):415-428.doi:10.1111/j.1365-2133.2010.10030.x 

20. Hong E, Smith S, Fischer G. Evaluation of the atrophogenic potential of topical corticosteroids in pediatric dermatology patients. Pediatr Dermatol.2011;28(4):393-396. doi:10.1111/j.1525-1470.2011.01445.x 

21. Hajar T, Leshem YA, Hanifin JM, et al. A systematic review of topical corticosteroid withdrawal (“steroid addiction”) in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol. 2015;72(3):541-549.e2. doi:10.1016/j.jaad.2014.11.024. 

22. Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol. 2007;156(2):203-221.doi:10.1111/j.1365-2133.2006.07538.x

23. Ntuen E, Taylor SL, Kinney M, O’Neill JL, Krowchuk DP, Feldman SR. Physicians’ perceptions of an eczema action plan for atopic dermatitis. J Dermatol Treat. 2010;21(1):28-33. doi:10.3109/09546630903386598. 

24. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ.2005;330(7490):516. doi:10.1136/bmj.38376.439653.D3. 

25. Thaçi D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol. 2008;159(6):1348-1356. doi:10.1111/j.1365-2133.2008.08813.x 

26. Wollenberg A, Reitamo S, Girolomoni G, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy.2008;63(7):742-750. 

27. Leo Pharma Inc. Protopic Product Monograph. Thornhill, Ontario:Leo Pharma Inc.; 2016. 

28. Valeant Canada. Elidel — Product Monograph. Laval, Quebec:Valeant Canada; 2014. 

29. Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol.2011;165(3):465-473. doi:10.1111/j.1365-2133.2011.10363.x 

30. Ring J, Möhrenschlager M, Henkel V. The US FDA “black box” warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf.2008;31(3):185-198. 

31. Canadian Dermatology Association. Topical Calcineurin Inhibitors Position Statement. Canadian Dermatology Association. https://dermatology.ca/tci-position-statement/. Published May 2018. Accessed September 6, 2018. 

32. Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494-503.e6. doi:10.1016/j.jaad.2016.05.046. 

33. Zane LT, Chanda S, Jarnagin K, Nelson DB, Spelman L, Gold LS. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies. Immunotherapy. 2016;8(8):853-866.doi:10.2217/imt-2016-0023. 

34. Pfizer Canada. Eucrisa — Product Monograph. Kirkland, Quebec:Pfizer Canada; 2018. 

35. Jarnagin K, Chanda S, Coronado D, et al. Crisaborole Topical Ointment, 2%:A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis. J Drugs Dermatol JDD. 2016;15(4):390-396. 

36. 36. Meduri NB, Vandergriff T, Rasmussen H, Jacobe H. Phototherapy in the management of atopic dermatitis: a systematic review. Photodermatol Photoimmunol Photomed. 2007;23(4):106-112. doi:10.1111/j.1600-0781.2007.00291.x 

37. Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol. 2016;30(5):729-747.doi:10.1111/jdv.13599. 

38. Gooderham M, Lynde CW, Papp K, et al. Review of Systemic Treatment Options for Adult Atopic Dermatitis. J Cutan Med Surg.2016:1203475416670364. 

39. Shah N, Alhusayen R, Walsh S, Shear NH. Methotrexate in the Treatment of Moderate to Severe Atopic Dermatitis: A Retrospective Study. J Cutan Med Surg. June 2018:120347541878133.doi:10.1177/1203475418781336. 

40. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet Lond Engl.2017;389(10086):2287-2303. doi:10.1016/S0140-6736(17)31191-1. 

41. Drucker AM, Eyerich K, de Bruin-Weller MS, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018;178(3):768-775.doi:10.1111/bjd.15928. 

42. Balma-Mena A, Lara-Corrales I, Zeller J, et al. Colonization with communityacquired methicillin-resistant Staphylococcus aureus in children with atopic dermatitis: a cross-sectional study. Int J Dermatol. 2011;50(6):682-688.doi:10.1111/j.1365-4632.2010.04751.x 

43. Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol. 2010;163(1):12-26. doi:10.1111/j.1365-2133.2010.09743.x 

44. Hon KL, Tsang YCK, Lee VWY, et al. Efficacy of sodium hypochlorite (bleach) baths to reduce Staphylococcus aureus colonization in childhood onset moderate-to-severe eczema: A randomized, placebo-controlled cross-over trial. J Dermatol Treat. 2016;27(2):156-162. doi:10.3109/09546634.2015.1067669. 

45. Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics. 2009;123(5):e808-814.doi:10.1542/peds.2008-2217. 

46. Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the pediatric population. Pediatrics. 2008;122(4):812-824. doi:10.1542/peds.2007-2232. 

47. Aronson PL, Yan AC, Mittal MK, Mohamad Z, Shah SS. Delayed Acyclovir and Outcomes of Children Hospitalized With Eczema Herpeticum. Pediatrics.2011;128(6):1161-1167. doi:10.1542/peds.2011-0948. 

48. Boyce JA, Assa’ad A, Burks AW, et al. Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. Nutr Res N Y N. 2011;31(1):61-75.doi:10.1016/j.nutres.2011.01.001. 

49. Ersser SJ, Cowdell F, Latter S, et al. Psychological and educational interventions for atopic eczema in children. Cochrane Database Syst Rev.2014;(1):CD004054. doi:10.1002/14651858.CD004054.pub3. 

50. Barbarot S, Stalder JF. Therapeutic patient education in atopic eczema. Br J Dermatol. 2014;170 Suppl 1:44-48. doi:10.1111/bjd.12932. 

51. Breuer K, Matterne U, Diepgen TL, et al. Predictors of benefit from an atopic dermatitis education programme. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 2014;25(5):489-495.doi:10.1111/pai.12249. 

52. Stalder J-F, Bernier C, Ball A, et al. Therapeutic patient education in atopic dermatitis: worldwide experiences. Pediatr Dermatol. 2013;30(3):329-334.doi:10.1111/pde.12024. 

53. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142(5):931-936. 

54. Chisolm SS, Taylor SL, Balkrishnan R, Feldman SR. Written action plans: potential for improving outcomes in children with atopic dermatitis. J Am Acad Dermatol. 2008;59(4):677-683. doi:10.1016/j.jaad.2008.04.025.